Market News

4 min read | Updated on November 18, 2026, 17:10 IST
SUMMARY
On November 18, the 30-share BSE SENSEX slumped 500.38 points or 0.61% to close at 82,031.81, while the 50-share NIFTY fell by 159.45 points or 0.63% to end at 25,227.95.
Stock list

On November 18, the NIFTY Smallcap 100 closed at 19,331.60, down by 67.10 points or 0.35%. | Image: Shutterstock
The SENSEX tumbled as much as 0.91% to hit an intraday low of 81,780.47. Meanwhile, the NIFTY50 slumped as much as 0.97% to reach the day’s low of 25,141.80.
On November 18, the 30-share BSE SENSEX slumped 500.38 points or 0.61% to close at 82,031.81, while the 50-share NIFTY fell by 159.45 points or 0.63% to end at 25,227.95.
Titan Company (-4.24%), HDFC Life Insurance Company (-3.08%), Hindalco Industries (-2.99%), Jio Financial Services (-2.44%), and Adani Enterprises (-2.36%) were among the top losers.
On the other hand, the top gainers included Cipla (2.85%), Tata Consumer Products (0.61%), Dr. Reddy’s Laboratories (0.50%), Trent (0.44%) and Oil and Natural Gas Corporation (ONGC) (0.37%).
NSE’s NIFTY midcap gauge, the Midcap 100, ended 1.22% or 750.65 points lower at 60,979.35 on November 18.
The index was weighed down by selling in the shares of Kalyan Jewellers India (-4.80%), Steel Authority of India Ltd (SAIL) (-4.27%), Swiggy (-4.25%), National Aluminium Company (-3.99%) and Dixon Technologies (-3.56%), which were among the other top laggards.
On the flip side, the top winners included Exide Industries (2.25%), Indian Renewable Energy Development Agency (IREDA) (2.04%), Ashok Leyland (1.21%), Glenmark Pharmaceuticals (1.16%) and Lupin Ltd (1.12%).
The stock of Glenmark Pharmaceuticals advanced after its subsidiary, Ichnos Glenmark Innovation (IGI), announced that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA).
The application was submitted for ISB 2301, an investigational multispecific immune cell activator being developed to target solid tumours, according to a regulatory filing.
The drug candidate is designed to target three tumour-associated antigens while engaging both T cells and natural killer (NK) cells to activate the immune system against cancer cells. IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumours in 2027.
The NIFTY Smallcap 100 closed at 19,331.60, down by 67.10 points or 0.35%.
The top losers included CreditAccess Grameen (-5.59%), Firstsource Solutions (-4.66%), Manappuram Finance (-4.26%), Devyani International (-3.98%), and Computer Age Management Services (-3.76%).
On the contrary, Urban Company (6.73%), Sterlite Technologies (5%), HFCL Ltd (4.99%), Navin Fluorine International (4.72%), and IIFL Finance (4.34%) were among the top gainers.
Shares of IIFL Finance soared after a large block deal involving the company's shares was executed in the first trading session of the day.
The transaction is understood to involve FIH Mauritius Investments Limited, an investment arm of Canada's Fairfax Financial Holdings, which had put its entire stake in IIFL Finance on the block.
Related News
About The Author

Next Story